{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T09:12:31Z","timestamp":1775207551227,"version":"3.50.1"},"reference-count":45,"publisher":"China Science Publishing & Media Ltd.","issue":"3","content-domain":{"domain":["engine.scichina.com"],"crossmark-restriction":false},"short-container-title":["ABBS"],"published-print":{"date-parts":[[2026,3,1]]},"DOI":"10.3724\/abbs.2025142","type":"journal-article","created":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T09:22:57Z","timestamp":1754644977000},"page":"530-540","update-policy":"https:\/\/doi.org\/10.1360\/scp-crossmark-policy-page","source":"Crossref","is-referenced-by-count":0,"title":["Combined ex vivo and in vivo evaluation of dolutegravir embryotoxicity: NTDs and yolk sac vascular abnormalities"],"prefix":"10.3724","volume":"58","author":[{"given":"Ruifang","family":"Ao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ran","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zelin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guicai","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haoran","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuecong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiayi","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaozheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2026","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"key":"CITATION1","doi-asserted-by":"publisher","first-page":"1222002","DOI":"10.1126\/science.1222002","volume":"339","author":"Wallingford JB","year":"2013","unstructured":"Wallingford JB, Niswander LA, Shaw GM, Finnell RH. The continuing challenge of understanding, preventing, and treating neural tube defects. Science, 2013, 339: 1222002.","journal-title":"Science"},{"key":"CITATION2","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1146\/annurev-neuro-062012-170354","volume":"37","author":"Greene NDE","year":"2014","unstructured":"Greene NDE, Copp AJ. Neural tube defects. Annu Rev Neurosci, 2014, 37: 221-242.","journal-title":"Annu Rev Neurosci"},{"key":"CITATION3","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/S1474-4422(13)70110-8","volume":"12","author":"Copp AJ","year":"2013","unstructured":"Copp AJ, Stanier P, Greene ND. Neural tube defects: recent advances, unsolved questions, and controversies. Lancet Neurol, 2013, 12: 799-810.","journal-title":"Lancet Neurol"},{"key":"CITATION4","doi-asserted-by":"publisher","first-page":"e357","DOI":"10.1016\/S2352-3018(18)30092-4","volume":"5","author":"Molina JM","year":"2018","unstructured":"Molina JM, Ward D, Brar I, Mills A, Stellbrink HJ, L\u00f3pez-Cort\u00e9s L, Ruane P. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet HIV, 2018, 5: e357-e365.","journal-title":"Lancet HIV"},{"key":"CITATION5","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1093\/jac\/dkv358","volume":"71","author":"Schalkwijk S","year":"2016","unstructured":"Schalkwijk S, Greupink R, Colbers AP, Wouterse AC, Verweij VGM, van Drongelen J, Teulen M. Placental transfer of the HIV integrase inhibitor dolutegravir in an ex vivo human cotyledon perfusion model. J Antimicrob Chemother, 2016, 71: 480-483.","journal-title":"J Antimicrob Chemother"},{"key":"CITATION6","doi-asserted-by":"publisher","first-page":"e593","DOI":"10.1016\/S2352-3018(20)30231-9","volume":"7","author":"The Lancet HIV","year":"2020","unstructured":"The Lancet HIV. End resistance to dolutegravir roll-out. Lancet HIV, 2020, 7: e593.","journal-title":"Lancet HIV"},{"key":"CITATION7","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S2055-6640(20)30247-8","volume":"4","author":"Hill A","year":"2018","unstructured":"Hill A, Clayden P, Thorne C, Christie R, Zash R. Safety and pharmacokinetics of dolutegravir in HIV-positive pregnant women: a systematic review. J Virus Eradication, 2018, 4: 66-71.","journal-title":"J Virus Eradication"},{"key":"CITATION8","doi-asserted-by":"publisher","first-page":"e400","DOI":"10.1016\/S2352-3018(18)30093-6","volume":"5","author":"Dorward J","year":"2018","unstructured":"Dorward J, Lessells R, Drain PK, Naidoo K, de Oliveira T, Pillay Y, Abdool Karim SS. Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: Uncertainties and opportunities for implementation and research. Lancet HIV, 2018, 5: e400-e404.","journal-title":"Lancet HIV"},{"key":"CITATION9","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1056\/NEJMc1807653","volume":"379","author":"Zash R","year":"2018","unstructured":"Zash R, Makhema J, Shapiro RL. Neural-tube defects with dolutegravir treatment from the time of conception. N Engl J Med, 2018, 379: 979-981.","journal-title":"N Engl J Med"},{"key":"CITATION10","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1056\/NEJMoa1905230","volume":"381","author":"Zash R","year":"2019","unstructured":"Zash R, Holmes L, Diseko M, Jacobson DL, Brummel S, Mayondi G, Isaacson A. Neural-tube defects and antiretroviral treatment regimens in botswana. N Engl J Med, 2019, 381: 827-840.","journal-title":"N Engl J Med"},{"key":"CITATION11","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1056\/NEJMc1908155","volume":"381","author":"Raesima MM","year":"2019","unstructured":"Raesima MM, Ogbuabo CM, Thomas V, Forhan SE, Gokatweng G, Dintwa E, Petlo C. Dolutegravir use at conception\u2005-\u2005additional surveillance data from botswana. N Engl J Med, 2019, 381: 885-887.","journal-title":"N Engl J Med"},{"key":"CITATION12","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1097\/QAD.0000000000002289","volume":"33","author":"Cabrera RM","year":"2019","unstructured":"Cabrera RM, Souder JP, Steele JW, Yeo L, Tukeman G, Gorelick DA, Finnell RH. The antagonism of folate receptor by dolutegravir. AIDS, 2019, 33: 1967-1976.","journal-title":"AIDS"},{"key":"CITATION13","doi-asserted-by":"publisher","first-page":"103771","DOI":"10.1016\/j.ebiom.2021.103771","volume":"75","author":"Gilmore JC","year":"2022","unstructured":"Gilmore JC, Hoque MT, Dai W, Mohan H, Dunk C, Serghides L, Bendayan R. Interaction between dolutegravir and folate transporters and receptor in human and rodent placenta. EBioMedicine, 2022, 75: 103771.","journal-title":"EBioMedicine"},{"key":"CITATION14","doi-asserted-by":"crossref","unstructured":"Dolutegravir-induced neural tube defects in mice are folate responsive: erratum.  AIDS  2024, 38.","DOI":"10.1097\/01.aids.0001025684.42572.a9"},{"key":"CITATION15","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.3390\/ph15121533","volume":"15","author":"Foster EG","year":"2022","unstructured":"Foster EG, Gendelman HE, Bade AN. HIV-1 integrase strand transfer inhibitors and neurodevelopment. Pharmaceuticals, 2022, 15: 1533.","journal-title":"Pharmaceuticals"},{"key":"CITATION16","doi-asserted-by":"publisher","first-page":"101572","DOI":"10.1016\/j.bjid.2021.101572","volume":"25","author":"Kreitchmann R","year":"2021","unstructured":"Kreitchmann R, Oliveira FR, Sprinz E. Two cases of neural tube defects with dolutegravir use at conception in south Brazil. Braz J Infect Dis, 2021, 25: 101572.","journal-title":"Braz J Infect Dis"},{"key":"CITATION17","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/bdr2.1635","volume":"112","author":"Stanislaus DJ","year":"2020","unstructured":"Stanislaus DJ, Posobiec LM, Laffan SB, Solomon HM, Ziejewski MK, Romach EH. Absence of developmental and reproductive toxicity in animals exposed to dolutegravir. Birth Defects Res, 2020, 112: 245-261.","journal-title":"Birth Defects Res"},{"key":"CITATION18","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1002\/bdr2.1949","volume":"113","author":"Posobiec LM","year":"2021","unstructured":"Posobiec LM, Chapman SP, Murzyn SF, Rendemonti JE, Stanislaus DJ, Romach EH. No developmental toxicity observed with dolutegravir in rat whole embryo culture. Birth Defects Res, 2021, 113: 1190-1197.","journal-title":"Birth Defects Res"},{"key":"CITATION19","unstructured":"Irene E Z. Mouse Models of neural tube defects.  Adv Exp Med Biol  2020, 1236."},{"key":"CITATION20","doi-asserted-by":"publisher","first-page":"e606","DOI":"10.1016\/S2352-3018(23)00141-8","volume":"10","author":"Dontsova V","year":"2023","unstructured":"Dontsova V, Mohan H, Blanco C, Jao J, Greene NDE, Copp AJ, Zash R. Metabolic implications and safety of dolutegravir use in pregnancy. Lancet HIV, 2023, 10: e606-e616.","journal-title":"Lancet HIV"},{"key":"CITATION21","doi-asserted-by":"publisher","first-page":"82","DOI":"10.3390\/antiox14010082","volume":"14","author":"Cusato J","year":"2025","unstructured":"Cusato J, Mulasso A, Ferrara M, Manca A, Accardo G, Palermiti A, Antonucci M. How antiretroviral drug concentrations could be affected by oxidative stress, physical capacities and genetics: a focus on dolutegravir treated male PLWH. Antioxidants, 2025, 14: 82.","journal-title":"Antioxidants"},{"key":"CITATION22","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1146\/annurev-pharmtox-011112-140320","volume":"53","author":"Ma Q","year":"2013","unstructured":"Ma Q. Role of Nrf2 in oxidative stress and toxicity. Annu Rev Pharmacol Toxicol, 2013, 53: 401-426.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"CITATION23","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.4103\/1673-5374.235249","volume":"13","author":"Li RL","year":"2018","unstructured":"Li RL, Zhao WW, Gao BY. Advanced glycation end products induce neural tube defects through elevating oxidative stress in mice. Neural Regen Res, 2018, 13: 1368.","journal-title":"Neural Regen Res"},{"key":"CITATION24","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.freeradbiomed.2018.01.004","volume":"116","author":"Lin S","year":"2018","unstructured":"Lin S, Ren A, Wang L, Huang Y, Wang Y, Wang C, Greene ND. Oxidative stress and apoptosis in benzo[a]pyrene-induced neural tube defects. Free Radical Biol Med, 2018, 116: 149-158.","journal-title":"Free Radical Biol Med"},{"key":"CITATION25","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13148-019-0673-6","volume":"11","author":"Huang Y","year":"2019","unstructured":"Huang Y, Ren A, Wang L, Jin L, Lin S, Li Z, McDonald JA. Casp8 hypomethylation and neural tube defects in association with polycyclic aromatic hydrocarbon exposure. Clin Epigenet, 2019, 11: 72.","journal-title":"Clin Epigenet"},{"key":"CITATION26","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1002\/bdr2.1094","volume":"109","author":"Wang L","year":"2017","unstructured":"Wang L, Lin S, Yi D, Huang Y, Wang C, Jin L, Liu J. Apoptosis, expression of PAX3 and P53, and caspase signal in fetuses with neural tube defects. Birth Defects Res, 2017, 109: 1596-1604.","journal-title":"Birth Defects Res"},{"key":"CITATION27","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/wdev.71","volume":"2","author":"Copp AJ","year":"2013","unstructured":"Copp AJ, Greene NDE. Neural tube defects-disorders of neurulation and related embryonic processes. WIREs Dev Biol, 2013, 2: 213-227.","journal-title":"WIREs Dev Biol"},{"key":"CITATION28","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1146\/annurev-genet-120213-092208","volume":"48","author":"Wilde JJ","year":"2014","unstructured":"Wilde JJ, Petersen JR, Niswander L. Genetic, epigenetic, and environmental contributions to neural tube closure. Annu Rev Genet, 2014, 48: 583-611.","journal-title":"Annu Rev Genet"},{"key":"CITATION29","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1002\/bdra.20705","volume":"88","author":"Zohn IE","year":"2010","unstructured":"Zohn IE, Sarkar AA. The visceral yolk sac endoderm provides for absorption of nutrients to the embryo during neurulation. Birth Defects Res, 2010, 88: 593-600.","journal-title":"Birth Defects Res"},{"key":"CITATION30","doi-asserted-by":"publisher","first-page":"3760","DOI":"10.1038\/s41467-020-17575-w","volume":"11","author":"Ross C","year":"2020","unstructured":"Ross C, Boroviak TE. Origin and function of the yolk sac in primate embryogenesis. Nat Commun, 2020, 11: 3760.","journal-title":"Nat Commun"},{"key":"CITATION31","doi-asserted-by":"publisher","first-page":"145S","DOI":"10.1016\/S0031-6997(25)06792-4","volume":"36","author":"Sadler TW","year":"1984","unstructured":"Sadler TW, Warner CW. Use of whole embryo culture for evaluating toxicity and teratogenicity. Pharmacol Rev, 1984, 36: 145S-150S.","journal-title":"Pharmacol Rev"},{"key":"CITATION32","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1002\/bdr2.1538","volume":"111","author":"Culshaw LH","year":"2019","unstructured":"Culshaw LH, Savery D, Greene NDE, Copp AJ. Mouse whole embryo culture: evaluating the requirement for rat serum as culture medium. Birth Defects Res, 2019, 111: 1165-1177.","journal-title":"Birth Defects Res"},{"key":"CITATION33","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41586-021-03416-3","volume":"593","author":"Aguilera-Castrejon A","year":"2021","unstructured":"Aguilera-Castrejon A, Oldak B, Shani T, Ghanem N, Itzkovich C, Slomovich S, Tarazi S. Ex utero mouse embryogenesis from pre-gastrulation to late organogenesis. Nature, 2021, 593: 119-124.","journal-title":"Nature"},{"key":"CITATION34","doi-asserted-by":"publisher","first-page":"152443","DOI":"10.1016\/j.tox.2020.152443","volume":"439","author":"Ao RF","year":"2020","unstructured":"Ao RF, Liang YX, Liu XQ, Tan K, Wang X, Liu D, Zhang T. Stavudine exposure results in developmental abnormalities by causing DNA damage, inhibiting cell proliferation and inducing apoptosis in mouse embryos. Toxicology, 2020, 439: 152443.","journal-title":"Toxicology"},{"key":"CITATION35","doi-asserted-by":"publisher","first-page":"1459877","DOI":"10.3389\/fnmol.2024.1459877","volume":"17","author":"LaNoce E","year":"2024","unstructured":"LaNoce E, Zhang DY, Garcia-Epelboim A, Su Y, Sun Y, Alepa G, Angelucci AR. Exposure to the antiretroviral drug dolutegravir impairs structure and neurogenesis in a forebrain organoid model of human embryonic cortical development. Front Mol Neurosci, 2024, 17: 1459877.","journal-title":"Front Mol Neurosci"},{"key":"CITATION36","doi-asserted-by":"publisher","first-page":"4640","DOI":"10.3390\/ijms25094640","volume":"25","author":"Zizioli D","year":"2024","unstructured":"Zizioli D, Quiros-Roldan E, Ferretti S, Mignani L, Tiecco G, Monti E, Castelli F. Dolutegravir and folic acid interaction during neural system development in zebrafish embryos. Int J Mol Sci, 2024, 25: 4640.","journal-title":"Int J Mol Sci"},{"key":"CITATION37","doi-asserted-by":"publisher","first-page":"103167","DOI":"10.1016\/j.ebiom.2020.103167","volume":"63","author":"Mohan H","year":"2021","unstructured":"Mohan H, Lenis MG, Laurette EY, Tejada O, Sanghvi T, Leung KY, Cahill LS. Dolutegravir in pregnant mice is associated with increased rates of fetal defects at therapeutic but not at supratherapeutic levels. EBioMedicine, 2021, 63: 103167.","journal-title":"EBioMedicine"},{"key":"CITATION38","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1016\/S2352-3018(20)30268-X","volume":"8","author":"Pereira GFM","year":"2021","unstructured":"Pereira GFM, Kim A, Jalil EM, Fernandes Fonseca F, Shepherd BE, Veloso VG, Rick F. Dolutegravir and pregnancy outcomes in women on antiretroviral therapy in Brazil: a retrospective national cohort study. Lancet HIV, 2021, 8: e33-e41.","journal-title":"Lancet HIV"},{"key":"CITATION39","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.3390\/antiox13121518","volume":"13","author":"Costa B","year":"2024","unstructured":"Costa B, Gouveia MJ, Vale N. Oxidative stress induced by antivirals: implications for adverse outcomes during pregnancy and in newborns. Antioxidants, 2024, 13: 1518.","journal-title":"Antioxidants"},{"key":"CITATION40","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1177\/1933719115625846","volume":"23","author":"Dong D","year":"2016","unstructured":"Dong D, Reece EA, Yang P. The Nrf2 activator vinylsulfone reduces high glucose-induced neural tube defects by suppressing cellular stress and apoptosis. Reprod Sci, 2016, 23: 993-1000.","journal-title":"Reprod Sci"},{"key":"CITATION41","doi-asserted-by":"publisher","first-page":"1394058","DOI":"10.3389\/fnmol.2024.1394058","volume":"17","author":"Caiaffa CD","year":"2024","unstructured":"Caiaffa CD, Tukeman G, Delgado CZ, Ambekar YS, Mekonnen TT, Singh M, Rodriguez V. Dolutegravir induces FOLR1 expression during brain organoid development. Front Mol Neurosci, 2024, 17: 1394058.","journal-title":"Front Mol Neurosci"},{"key":"CITATION42","doi-asserted-by":"publisher","DOI":"10.1126\/science.add7564","volume":"381","author":"Goh I","year":"2023","unstructured":"Goh I, Botting RA, Rose A, Webb S, Engelbert J, Gitton Y, Stephenson E. Yolk sac cell atlas reveals multiorgan functions during human early development. Science, 2023, 381.","journal-title":"Science"},{"key":"CITATION43","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/s41586-023-06914-8","volume":"626","author":"Hislop J","year":"2024","unstructured":"Hislop J, Song Q, Keshavarz F. K, Alavi A, Schoenberger R, LeGraw R, Velazquez JJ. Modelling post-implantation human development to yolk sac blood emergence. Nature, 2024, 626: 367-376.","journal-title":"Nature"},{"key":"CITATION44","doi-asserted-by":"publisher","first-page":"1073807","DOI":"10.3389\/fcell.2023.1073807","volume":"11","author":"Zhang M","year":"2023","unstructured":"Zhang M, Salbaum JM, Jones S, Burk D, Kappen C. Aberrant lipid accumulation in the mouse visceral yolk sac resulting from maternal diabetes and obesity. Front Cell Dev Biol, 2023, 11: 1073807.","journal-title":"Front Cell Dev Biol"},{"key":"CITATION45","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ajog.2015.09.082","volume":"214","author":"Dong D","year":"2016","unstructured":"Dong D, Reece EA, Lin X, Wu Y, AriasVillela N, Yang P. New development of the yolk sac theory in diabetic embryopathy: molecular mechanism and link to structural birth defects. Am J Obstet Gynecol, 2016, 214: 192-202.","journal-title":"Am J Obstet Gynecol"}],"container-title":["Acta Biochimica et Biophysica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.sciengine.com\/doi\/pdf\/F5FE7FF386EE4D6AA0BBEE144838284A","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.sciengine.com\/doi\/10.3724\/abbs.2025142","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.sciengine.com\/doi\/pdf\/F5FE7FF386EE4D6AA0BBEE144838284A","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T08:14:32Z","timestamp":1775204072000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.sciengine.com\/doi\/10.3724\/abbs.2025142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":45,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,11,3]]},"published-print":{"date-parts":[[2026,3,1]]}},"URL":"https:\/\/doi.org\/10.3724\/abbs.2025142","relation":{},"ISSN":["1672-9145"],"issn-type":[{"value":"1672-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,3]]}}}